Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
BioOptics Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Rhythm Pharmaceuticals, Inc.
< Previous
1
2
Next >
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
August 13, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update
August 06, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old
July 31, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity
July 23, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
July 23, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
July 11, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer
July 08, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency
June 28, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
June 11, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
June 03, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
June 03, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
May 22, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
May 09, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
May 07, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
May 06, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
April 29, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
April 24, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
April 16, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
April 01, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
March 25, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
March 11, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
March 06, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
February 22, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
February 22, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
February 08, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
February 07, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
January 31, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
January 12, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640
January 04, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates
January 04, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RYTM
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.